中国日报

68岁的北京人说他的妻子已经更多的慢性疾病和药物治疗的成本甚至更多,而他的两个儿子,42岁,38岁,还需要每天吃药高血压和心脏疾病。 Wang and his family are among the more than 260 million Chinese people, around a quarter of the nation’s population, who have been diagnosed with chronic diseases, including cardiovascular diseases, diabetes, cancer and chronic respiratory diseases.

The Ministry of Health said that around 10 million people in China have contracted chronic diseases every year since 2002.

\"Prevention and control of chronic diseases will be one of the seven top tasks of China’s medical care reform by 2020,\" said Health Minister Chen Zhu.

The central government will invest a total of 400 billion yuan by 2020 in the seven key projects, which also involve improvements to the grassroots healthcare system, psychological disease prevention, the construction of a digital public health information network, medical device innovation, the development of traditional Chinese medicine, and the training of general practitioners.

According to the ministry, 85 percent of deaths in China are caused by chronic diseases, with expenditure on the treatment of these accounting for 69 percent of China’s total healthcare costs last year.

小王和他的家人都在超过2.6亿名中国人,大约四分之一的国家的人口,他被诊断出患有慢性疾病,包括心血管疾病、糖尿病、癌症和慢性呼吸道疾病。 卫生部说,中国每年大约有1000万人感染慢性疾病自2002年以来每年。 “预防和控制慢性疾病将七大任务之一的中国医疗保健改革到2020年,“说,卫生陈竺。

将投资总额4000亿元的人民币到2020年的7个关键项目,这也包括改善基层卫生保健系统,心理疾病预防,建设数字公共卫生信息网络、医疗设备的创新,发展中国传统医学,并培训全科医生。

根据国防部消息,在中国85%的死亡是由于慢性疾病,治疗这些支出占中国总人口的69%,去年的医疗成本。

Foreign pharmaceutical companies have an advantage in this sector, according to Song Yingtong, a senior analyst at Beijing Chnmed Consulting Co Ltd, a domestic pharmaceutical consulting firm. \"They have accumulated rich experience in chronic disease treatment in developed markets,\" he said. International drugmakers

Developed economies witnessed a rise in chronic diseases in the late 1980s. China, along with fast economic growth, is now experiencing the growth of these \"illnesses of affluence\by a rich diet, less exercise and heavy physiological pressure, Song said.

China’s market for chronic disease medication is already highly competitive.

The diabetes sector is led by Denmark’s Novo Nordisk AS, US-based Eli Lilly and Co and Germany’s Bayer HealthCare. Meanwhile

Switzerland’s Novartis AG and UK-based GlaxoSmithKline Plc are well placed in the treatment of cardiovascular diseases. In cancer therapy, Pfizer Inc from the United States and Merck Sharp & Dohme Corp — known in the US and Canada as Merck & Co — are taking the lead. And

they are now stepping up their efforts to further explore the market in China.

外国制药公司在这方面有优势,根据歌曲《高级分析师北京Chnmed咨询有限公司,国内制药咨询公司。

“他们已经积累了丰富的经验在慢性疾病治疗在发达市场,”他说。 国际制药公司

发达经济体见证慢性病上升在1980年代末。中国,随着经济快速增长,正经历着成长的这些“富贵病”,这主要是由于丰富的饮食,锻炼和沉重的生理压力更少,宋说。

中国市场对于慢性疾病药物已经高度竞争的。

糖尿病的部门是由丹麦诺和诺德公司,美国礼来公司和德国拜耳医药保健有限公司。与此同时瑞士的诺华制药公司和英国葛兰素史克都放置在心血管疾病的治疗。在癌症治疗,辉瑞公司从美国和默沙东&这个集团中被称为“美国和加拿大作为默克公司——正在带头。现在,他们正加紧努力,进一步探索中国市场。 US-based Bristol-Myers Squibb Co plans to launch at least five new products by 2020 in China, which are all targeted at chronic diseases. Jean-Christophe Pointeau, president of BMS (China) Investment Co Ltd, said that his company has set its business focus in China on diabetes, hepatitis, cardiovascular and metabolic conditions, and cancer therapies.

Ranked as one of the world’s top 10 biophamarceutical companies, BMS launched a new diabetes medicine in China last November and plans to promote a new cardiovascular medication under joint development with Pfizer Inc this year. Two more new diabetes drugs are expected to come on to the market between 2013 and 2014, and there are plans to launch a range of cancer and anti-viral medicines between 2015 and 2016.

\"We have a busy schedule before 2020,\" said Pointeau, who took up his current post in June 2011.

Previously, the US-based company had only launched one new drug in China over the past 10 years. China is BMS’ fifth-largest market, with sales rising by 10 to 15 percent annually over the past five years. Pointeau said the company will maintain this growth momentum in the years to come.

MSD, the world’s second-largest drug producer by sales, announced at the end of last year it will invest $1.5 billion in research and

development in China within five years, with a large part of the funds devoted to the development of chronic disease medicines tailored to local pe美国百时美施贵宝公司计划推出新产品至少五到2020年在中国,这些都是针对慢性疾病。

克里斯多夫·Pointeau,总统的BMS(中国)投资有限公司,说他的公司已将其业务集中在中国对糖尿病、肝炎、心血管和代谢条件,和癌症治疗。

排名全球前10个biophamarceutical公司,BMS启动了一个新的糖尿病药物在中国去年11月和计划促进新的心血管药物在联合开发与今年辉瑞公司。两个新的糖尿病药物有望加入这个市场在2013年和2014年之间,正准备推出一系列癌症和抗病毒药物在2015年和2016年之间。

“我们有一个繁忙的时间表在2020年之前,“Pointeau说,他拿起他目前的职位在2011年6月。

此前,美国公司只有在中国推出一个新的药物过去10年。中国第五大市场,BMS销售上升了10至每年15%在过去的五年里。Pointeau表示,该公司将维持这种增长势头在未来几年。

默沙东,世界第二大药品生产商的销售,去年年底宣布它将投资15亿美元在研究和开发在五年内在中国,很大一部分资金用于发展的慢性病药物适合当地的人

The company is building an Asia research and development

headquarters in Beijing and is cooperating with local counterparts and academic institutions.

Michel Vounatsos, chairman and president of MSD China, said that the new R&D center, an integrated part of the company’s global research

network, will speed up the introduction of the company’s newly developed medicines to China as well as cooperation with local partners that will help create products tailored to Chinese patients. Domestic players

Beijing resident Deng said that he and his wife’s expenditure on chronic disease treatment has increased in the past few years. \"The doctors usually recommend medicine made by foreign

companies or joint ventures to us. I prefer domestic products, which are in general cheaper and have a similar effect,\" he said.

Compared with foreign companies, domestic drugmakers have the upper hand in terms of price, because their products are mainly generics.

Generic drugs are comparable to original drugs in terms of dosage, strength, quality and performance characteristics, and intended use. They can be marketed after the patent for the original drug expires, thus the prices of generics are much lower than the original medication.

In addition to price, domestic companies have their own advantages in various regions, said Wang Linhong, deputy director of the

non-epidemic chronic disease control and prevention bureau affiliated to the Ministry of Health.

该公司正在建造一个亚洲研究和发展总部在北京和正在配合当地同行和学术机构。

米歇尔Vounatsos总裁兼董事长MSD中国,说,新的研发中心,一个集成部分公司的全球研究网络,将加快引进公司的新开发药物来中国以及与当地伙伴合作,帮助中国患者创建定制的产品。 国内球员

北京市民邓说,他和他的妻子在慢性疾病治疗的支出增加了在过去的几年里。 “医生通常建议医学由外国公司或合资企业给我们。我更钟情于国内的产品,一般来说更便宜,也有相似的效果,”他说。

与外国公司相比,国内制药商占上风在价格上,因为他们的产品主要是泛型。 仿制药与原研药剂量而言,强度、质量和性能特点,并预期用途。他们可以上市后药物的专利到期的原始,因此价格的泛型远低于最初的药物。

除了价格,国内企业有自己的优势在不同的地区,王说,副主任临导致幼儿罹患非流行性慢性疾病控制和预防局隶属于卫生部。

\"Even with the same disease, the symptoms of patients in different areas may be somewhat different, so many local companies have their own products specifically tailored to local patients,\" she said, adding

that companies with these kinds of medication are really competitive in regional markets.

According to Frank Guo, director of Ipsos Healthcare China, substantial investment will be made in different parts of the chronic disease management cycle — public education, health food products, and disease prevention.

Private companies are already playing quite an active role in chronic disease management. There are already many innovative Chinese private pharmaceutical companies that have a considerable presence in chronic disease therapy.

Private pharmaceutical companies and private medical device companies that develop and manufacture chronic disease related products such as testing equipment and therapeutic devices will benefit from this.

“即使有相同的疾病,这些症状的患者在不同的地区可能有所不同,所以许多当地的公司都有自己的产品专为当地病人,”她说,并补充说,公司与这些类型的药物确实是在区域市场竞争。

据弗兰克·郭主任,中国大量投资益普索卫生保健,将不同地区的慢性疾病管理循环——公共教育,健康食品,和疾病预防。

私人公司已经玩一个相当积极的作用慢性病管理。已经有许多创新的中国私营制药公司,有一个很大的份额在慢性疾病的疗法。

私有制药公司和私人医疗设备公司,开发和制造慢性病相关产品,如测试设备和治疗设备将从中受益。

We expect to see increased government funding for purchase of these types of devices, as well as a rising reimbursement level for patients which would make the tests and treatment more affordable,\" Guo said. Reimbursement list

\"The new initiative will probably lead to expanded reimbursement coverage for many of the drugs to treat chronic diseases, and will in turn lead to increased drug sales,\" said Guo.

Deng Mingliang, the son of Deng Jianping, said: \"Some of the medicines I am using are not on the reimbursement list. But due to their quality, I choose the more effective, usually more expensive, ones. As a result, my expenditure is much higher than my parents’,\" he said. China has a national essential drugs list, which was compiled by the National Development and Reform Commission. It focuses on common diseases, mainly chronic ones, and identifies drugs available to the public at all times, in appropriate dosages and at affordable prices.

In addition to the national list, regional governments can add medicines to their reimbursement lists in line with local medical and economic conditions.

So far, the national list covers 307 essential medicines, more than 90 percent of which are generics. The regional lists usually include more than 1,000 items, with original drugs only accounting for a small part. \"Price is the first consideration of the lists, then effect and quality are taken into account,\" said Wu Yiling, a scholar at the Chinese Academy of Engineering. \"I believe the list should be expanded to offer more choices to patients.\"

Health Minister Chen Zhu said at this year’s session of the National People’s Congress in March that China will add about 400 Western drugs and 200 traditional Chinese medicines to the national essential drugs list this year. The local lists are expected to be expanded at a later date.

The ministry even considered putting medication to help people quit smoking on the list, but this attracted public criticism.

The critics said there are only three such kinds of medication available in China, all of which are developed and produced by international pharmaceutical giants and are very expensive.

\"How to adjust the list — coordinating the interests of the public, the nation and businesses — is really a difficult problem to be resolved by the central government,\" said Wu

我们期待看到增加的资金购买这些类型的设备,以及不断上升的还款水平对病人,这样将使测试和治疗更便宜,”郭说。 报销清单

“新计划可能会导致扩大报销覆盖许多药物来治疗慢性疾病,并反过来导致更多的药品销售,”郭说。

明梁,邓建平的儿子说:“我的一些药物使用并不在报销清单。但由于其质量,我选择了更有效的,通常更加昂贵,。因此,我的支出远高于我的父母,”他说。

中国有一个国家基本药物清单,这是编译由国家发展和改革委员会。它着重于常见疾病,主要慢性病,并确定药物提供给公众的时刻,在适当的剂量和可负担得起的价格。

除了国家列表,地方可以增加他们的还款的药物名单符合当地医疗和经济条件。

到目前为止,国家基本药物清单涵盖了307年,超过90%的仿制药。区域列表通常包括超过1000个项目,与原药物只占一小部分。

“首先要考虑的是价格的列表,然后效应和质量都考虑进去,”吴宜林学者中国工程院院士。“我相信这个清单应扩展到对病人提供更多选择。”

卫生陈竺说在今年的全国人民代表大会会议在3月,中国将增加约400西方药物和200中国传统药物的国家基本药物清单今年。当地的名单预计将扩大在稍后的日期。

国防部甚至还考虑将药物来帮助人们戒烟的名单,但这吸引了公众的批评。 评论家们说,只有三个这种类型的药物可以在中国,所有的这些都是研制生产的国际制药巨头和非常昂贵。

“如何调整清单——协调公众的利益、国家和企业——确实是一个困难的问题需要解决,由。”邬说